{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:05:01Z","timestamp":1792062301833,"version":"4.4.0"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,2,3]],"date-time":"2014-02-03T00:00:00Z","timestamp":1391385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2014,4]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n \n Primary myelofibrosis (\n PMF<\/jats:styled-content>\n ), essential thrombocythemia (\n ET<\/jats:styled-content>\n ), and polycythemia vera (\n PV<\/jats:styled-content>\n ) are\n BCR ABL<\/jats:styled-content>\n \u2010negative myeloproliferative neoplasms (\n MPN<\/jats:styled-content>\n ). Published epidemiology data are scarce, and multiple sources are needed to assess the disease burden.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We assembled the most recent information available on the incidence and prevalence of myelofibrosis (\n MF<\/jats:styled-content>\n ),\n ET<\/jats:styled-content>\n , and\n PV<\/jats:styled-content>\n by conducting a structured and exhaustive literature review of the published peer\u2010reviewed literature in\n EMBASE<\/jats:styled-content>\n and by reviewing online documentation from disease registries and relevant health registries in European countries. The search was restricted to human studies written in English or French and published between January 1, 2000, and December 6, 2012.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Eleven articles identified from\n EMBASE<\/jats:styled-content>\n , three online hematology or oncology registries, and two Web\u2010based databases or reports were used to summarize epidemiological estimates for\n MF<\/jats:styled-content>\n ,\n PV<\/jats:styled-content>\n , and\n ET<\/jats:styled-content>\n . The incidence rate of\n MF<\/jats:styled-content>\n ranged from 0.1 per 100\u00a0000 per year to 1 per 100\u00a0000 per year. Among the various registries, the incidence of\n PV<\/jats:styled-content>\n ranged from 0.4 per 100\u00a0000 per year to 2.8 per 100\u00a0000 per year, while the literature estimated the range of\n PV<\/jats:styled-content>\n incidence to be 0.68 per 100\u00a0000 to 2.6 per 100\u00a0000 per year. The estimated incidence of\n ET<\/jats:styled-content>\n was between 0.38 per 100\u00a0000 per year and 1.7 per 100\u00a0000 per year. While a few studies reported on the\n MPN<\/jats:styled-content>\n s' prevalences, it is difficult to compare them as various types of prevalence were calculated (point prevalence vs. period prevalence) and standardization was made according to different populations (e.g., the world population and the European population).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n There is a wide variation in both prevalence and incidence estimates observed across European data sources. Carefully designed studies, with standardized definitions of\n MPN<\/jats:styled-content>\n s and complete ascertainment of patients including both primary and secondary\n MF<\/jats:styled-content>\n s, should be conducted so that estimates of the population aimed to receive novel treatments for these neoplasms are better understood assist public health planning and provide valuable information about the burden of illness to policy makers, funding agencies, resource planners, healthcare insurers, and pharmaceutical manufacturers.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ejh.12256","type":"journal-article","created":{"date-parts":[[2013,12,24]],"date-time":"2013-12-24T03:26:41Z","timestamp":1387855601000},"page":"289-297","source":"Crossref","is-referenced-by-count":221,"title":["Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the\n E<\/scp>\n uropean\n U<\/scp>\n nion"],"prefix":"10.1111","volume":"92","author":[{"given":"Odile","family":"Moulard","sequence":"first","affiliation":[{"name":"Oncology\u2010Global Evidence and Value Development Medical Affairs Chilly\u2010Mazarin France USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotsna","family":"Mehta","sequence":"additional","affiliation":[{"name":"Oncology\u2010Global Evidence and Value Development Medical Affairs Sanofi Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Fryzek","sequence":"additional","affiliation":[{"name":"EpidStat Institute Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Olivares","sequence":"additional","affiliation":[{"name":"Oncology\u2010Global Evidence and Value Development Medical Affairs Chilly\u2010Mazarin France USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Oncology\u2010Global Evidence and Value Development Medical Affairs Sanofi Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Mayo Clinic Cancer Center Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,2,3]]},"reference":[{"key":"e_1_2_5_2_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_5_3_1","unstructured":"National Cancer Institute.Myeloproliferative disorders.http:\/\/www.cancer.gov\/cancertopics\/types\/myeloproliferative(Accessed 25 March 2013)."},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24440"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2864"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_5_7_1","first-page":"1400","article-title":"The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England","volume":"91","author":"Phekoo KJ","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21183"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830470205"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0344-0338(11)80081-6"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1986.9"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.06.032"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.01.035"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328955"},{"key":"e_1_2_5_15_1","unstructured":"International Association of Cancer Registries.www.iacr.com.fr(Accessed 30 November 2012)."},{"key":"e_1_2_5_16_1","unstructured":"European Network of Cancer Registries International Association of Cancer Registries World Health Organization.www.encr.com.fr(Accessed 30 November 2012)."},{"key":"e_1_2_5_17_1","unstructured":"Croatian National Institute of Public Health.Croatian National Cancer Registry.http:\/\/www.hzjz.hr\/cancer\/(Accessed 30 November 2012)."},{"key":"e_1_2_5_18_1","unstructured":"Cancer Statistics.Finnish Cancer Registry.http:\/\/www.cancer.fi\/syoparekisteri\/en\/(Accessed 30 November 2012)."},{"key":"e_1_2_5_19_1","unstructured":"Official Statistics of Sweden.Swedish Cancer Registry.http:\/\/www.socialstyrelsen.se\/register\/halsodataregister\/cancerregistret\/inenglish(Accessed 11 December 2012)."},{"key":"e_1_2_5_20_1","unstructured":"Registre des h\u00e9mopathies malignes de la Gironde.Quelques donn\u00e9es issues des 5 premi\u00e8res ann\u00e9es de recueil (periode 2002\u20132006). etudes.isped.u\u2010bordeaux2.fr\/REGISTRES\u2010CANCERS\u2010AQUITAINE\/ (Accessed 15 December 2012)."},{"key":"e_1_2_5_21_1","unstructured":"Orphanet.The portal for rare diseases and orphan drugs.http:\/\/www.orpha.net\/consor\/cgi-bin\/index.php(Accessed 1 December 2012)."},{"key":"e_1_2_5_22_1","unstructured":"RARECARE.Surveillance of rare cancers in Europe.www.rarecare.eu(Accessed 1 December 2012)."},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.004234"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2004.01357.x"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.245"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.450"},{"key":"e_1_2_5_27_1","first-page":"e14","article-title":"Hematological malignancies: incidence in Basse\u2010Normandie, France, for 1997\u20132004","volume":"57","author":"Troussard X","year":"2009","journal-title":"Rev Epid\u00e9miol Sant\u00e9 Publique"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1992.tb01788.x"},{"key":"e_1_2_5_29_1","doi-asserted-by":"crossref","unstructured":"Le Guyader\u2010PeyrouS GobertE MenardE ReiffersJ MonnereauA.Incidence et survie des cas incidents d'h\u00e9mopathies malignes de la Gironde diagnostiqu\u00e9s sur la p\u00e9riode 2002\u20132006. Communication appears to 6th days Canc\u00e9rop\u00f4le Southwest \u2013 Toulouse. October 2010.","DOI":"10.1016\/S0007-4551(15)31058-4"},{"issue":"2","key":"e_1_2_5_30_1","first-page":"587","article-title":"Prevalence of essential thrombocythemia in the JAK2V617F era: a population based study approach in a Spanish community hospital","volume":"94","author":"Mena\u2010Duran AV","year":"2009","journal-title":"Haematologica"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90236.x"},{"key":"e_1_2_5_32_1","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","author":"Mehta J","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_5_34_1","first-page":"159","article-title":"Epidemiological data in polycythaemia vera: a study of 842 cases","volume":"40","author":"Najean Y","year":"1998","journal-title":"Hematol Cell Ther"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12256","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:11:43Z","timestamp":1695539503000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,3]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1111\/ejh.12256"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12256","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,3]]}}}